
Akili outlines adult ADHD data for prescription video game; Medtech startup to go public via SPAC
The digital medicine biotech Akili Interactive revealed topline results from a trial for its video game-like digital therapy EndeavorRx, also known as AKL-TO1, in adults with ADHD, with some positive results.
On Wednesday, the biotech said the game produced a statistically significant improvement in attention functioning from patients after six weeks of treatment compared to placebo. Improvements were also noted in several secondary outcomes related to assessments of ADHD-related symptoms and quality of life metrics. Akili reported no serious side effects.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.